Hepatitis C virus infection in children in the era of direct-acting antiviral

Table 1 Ongoing clinical trials to evaluate the safety and efficacy of direct-acting antivirals in children with chronic hepatitis C

Trial identifier	Drug tested	HCV genotype
NCT 3067129	Glecaprevir/pibrentasvir	1-6
NCT 2486406	Ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin	1,4
NCT 3080415	Sofosbuvir + daclatasvir	4
NCT 2868242	Ledipasvir/sofosbuvir	1,4
NCT 2249182	Ledipasvir/sofosbuvir ± ribavirin	1,4,5,6
NCT 3022981	Sofosbuvir/velpatasvir	1-6
NCT 2985281	Gratisovir + ribavirin	1-6

HCV: Hepatitis C virus.

Table 2 Efficacy of direct-acting antivirals treatment of hepatitis C virus infected children and adolescents

Study	Patient population	HCV genotype	Drug	Duration of therapy (wk)	SVR 12 (%)
Balistreri et al[41]	100 adolescents aged 12-17 yr	1	ledipasvir 90 mg + sofosbuvir 400 mg	12	98
Murray et al[47]	90 children aged 6-11 yr	1	ledipasvir 45 mg + sofosbuvir 200 mg	12	98
Wirth et al[48]	13 adolescents aged 12-17 yr	2	sofosbuvir 400 mg + ribavirin 15 mg/kg	12	100
	39 adolescents aged 12-17 yr	3	sofosbuvir 400 mg + ribavirin 15 mg/kg	24	97
Hashmi et al [50]	35 children aged 5-18 yr	3,1	sofosbuvir 400 mg + ribavirin 10-15 mg/kg	24	97
Leung et al [52]	38 adolescents	1,4	ombitasvir 150 mg + paritaprevir 100 mg + ritonavir 25 mg ± dasabuvir 250 mg ± ribavirin	12-24	100
El-Sayed et al [53]	13/18 adolescents	4	sofosbuvir 400 mg + daclatasvir 60 mg ± ribavirin 15 mg/kg	8-12	100

HCV: Hepatitis C virus; SVR: Sustained virologic response.